Richard C. Koya

11.8k citations

78 papers · 7.5k indexed · 4 hit papers · h-index 36

Molecular Biology top 1%
Oncology top 0.5%
Immunology top 1%
Computational Theory and Mathematics top 0.5%
Pathology and Forensic Medicine top 2%

Co-authors: Antoni Ribas Thinle Chodon Roger S. Lo Xiangju Kong Hubing Shi Jeffrey A. Sosman Stephen Mok Stanley F. Nelson
Topics: Immunotherapy and Immune Responses (28 papers)CAR-T cell therapy research (25 papers)Melanoma and MAPK Pathways (16 papers)
Cited by: Oncology Immunology Molecular Biology
Journals: Nature Proceedings of the National Academy of Sciences Journal of the American Chemical Society
Partner nations: United States Brazil Japan

In The Last Decade

Richard C. Koya

77 papers receiving 7.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

2010 1.6k citations Ramin Nazarian, Hubing Shi et al. Nature profile →
Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

2013 715 citations Hubing Shi, Willy Hugo et al. Cancer Discovery profile →
Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance

2012 470 citations Hubing Shi, Gatien Moriceau et al. profile →
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF ^V600E melanoma

2015 435 citations Siwen Hu‐Lieskovan, Stephen Mok et al. Science Translational Medicine profile →

Peers

Countries citing papers authored by Richard C. Koya

Since Specialization

Citations

This map shows the geographic impact of Richard C. Koya's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard C. Koya with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard C. Koya more than expected).

Fields of papers citing papers by Richard C. Koya

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard C. Koya. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard C. Koya. The network helps show where Richard C. Koya may publish in the future.

Co-authorship network of co-authors of Richard C. Koya

This figure shows the co-authorship network connecting the top 25 collaborators of Richard C. Koya. A scholar is included among the top collaborators of Richard C. Koya based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard C. Koya. Richard C. Koya is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Tcf-1 protects anti-tumor TCR-engineered CD8+ T-cells from GzmB mediated self-destruction 2022 ·Cancer Immunology Immunotherapy ·(unknown),Takemasa Tsuji,Junko Matsuzaki,Hemn Mohammadpour,Cheryl Eppolito,Sebastiano Battaglia,Fumito Ito,Thinle Chodon,Richard C. Koya,AJ Robert McGray,Kunle Odunsi	4
2	Engineered microenvironment for the study of myofibroblast mechanobiology 2021 ·Wound Repair and Regeneration ·Ying Xu,Richard C. Koya,Kjetil Ask,Ruogang Zhao	7
3	Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy 2018 ·Cancer Immunology Research ·Takemasa Tsuji,(unknown),Junko Matsuzaki,Anthony Miliotto,(unknown),Richard C. Koya,Kunle Odunsi	13
4	Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF ^V600E melanomabreakdown → 2015 ·Science Translational Medicine ·Siwen Hu‐Lieskovan,Stephen Mok,Blanca Homet Moreno,Jennifer Tsoi,Lídia Robert,Lucas Goedert,Elaine M. Pinheiro,Richard C. Koya,Thomas G. Graeber,Begoña Comı́n-Anduix,Antoni Ribas	435
5	CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire 2014 ·Clinical Cancer Research ·Lídia Robert,Jennifer Tsoi,Xiaoyan Wang,Ryan Emerson,Blanca Homet,Thinle Chodon,Stephen Mok,Rong Huang,Alistair J. Cochran,Begoña Comı́n-Anduix,Richard C. Koya,Thomas G. Graeber,(unknown),Antoni Ribas	280
6	HSV-sr39TK Positron Emission Tomography and Suicide Gene Elimination of Human Hematopoietic Stem Cells and Their Progeny in Humanized Mice 2014 ·Cancer Research ·Eric H. Gschweng,Melissa McCracken,Michael L. Kaufman,Michelle Ho,Roger P. Hollis,Xiaoyan Wang,(unknown),Richard C. Koya,Thinle Chodon,Antoni Ribas,Owen N. Witte,Donald B. Kohn	26
7	Exposure to a Histone Deacetylase Inhibitor Has Detrimental Effects on Human Lymphocyte Viability and Function 2014 ·Cancer Immunology Research ·Deborah J. Wong,(unknown),Earl Avramis,Douglas Matsunaga,Kimberly M. Komatsubara,Mohammad Atefi,Helena Escuin-Ordinas,Thinle Chodon,Richard C. Koya,Antoni Ribas,Begoña Comı́n-Anduix	17
8	Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapybreakdown → 2013 ·Cancer Discovery ·Hubing Shi,Willy Hugo,Xiangju Kong,Aayoung Hong,Richard C. Koya,Gatien Moriceau,Thinle Chodon,Rongqing Guo,Douglas B. Johnson,Kimberly B. Dahlman,Mark C. Kelley,Richard Kefford,Bartosz Chmielowski,John A. Glaspy,Jeffrey A. Sosman,Nicolas van Baren,Georgina V. Long,Antoni Ribas,Roger S. Lo	715
9	Multifunctional T-cell Analyses to Study Response and Progression in Adoptive Cell Transfer Immunotherapy 2013 ·Cancer Discovery ·Chao Ma,Ann Cheung,Thinle Chodon,Richard C. Koya,Zhongqi Wu,Charles Ng,Earl Avramis,Alistair J. Cochran,Owen N. Witte,David Baltimore,Bartosz Chmielowski,James S. Economou,Begonya Comin-Anduix,Antoni Ribas,James R. Heath	112
10	A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition 2013 ·Cancer Discovery ·Hubing Shi,Aayoung Hong,Xiangju Kong,Richard C. Koya,Chunying Song,Gatien Moriceau,Willy Hugo,Clarissa C. Yu,Charles Ng,Thinle Chodon,Richard A. Scolyer,Richard Kefford,Antoni Ribas,Georgina V. Long,Roger S. Lo	133
11	Inhibition of CSF-1 Receptor Improves the Antitumor Efficacy of Adoptive Cell Transfer Immunotherapy 2013 ·Cancer Research ·Stephen Mok,Richard C. Koya,Christopher Tsui,Jingying Xu,Lídia Robert,Lily Wu,Thomas G. Graeber,Brian L. West,Gideon Bollag,Antoni Ribas	252
12	BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy 2012 ·Cancer Research ·Richard C. Koya,Stephen Mok,Nicholas Otte,(unknown),Begonya Comin-Anduix,Paul C. Tumeh,Aspram Minasyan,Nicholas A. Graham,Thomas G. Graeber,Thinle Chodon,Antoni Ribas	187
13	Preexisting MEK1 Exon 3 Mutations in V600E/K BRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors 2012 ·Cancer Discovery ·Hubing Shi,Gatien Moriceau,Xiangju Kong,Richard C. Koya,Ramin Nazarian,Gulietta M. Pupo,Antonella Bacchiocchi,Kimberly B. Dahlman,Bartosz Chmielowski,Jeffrey A. Sosman,Ruth Halaban,Richard Kefford,Georgina V. Long,Antoni Ribas,Roger S. Lo	75
14	CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans 2011 ·Clinical Cancer Research ·Rong Huang,Jason Jalil,James S. Economou,Bartosz Chmielowski,Richard C. Koya,Stephen Mok,Hooman Sazegar,Elizabeth Seja,Arturo Villanueva,Jesús Gómez-Navarro,John A. Glaspy,Alistair J. Cochran,Antoni Ribas	120
15	Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses 2010 ·Proceedings of the National Academy of Sciences ·Richard C. Koya,Stephen Mok,Begoña Comı́n-Anduix,Thinle Chodon,Caius G. Radu,Michael I. Nishimura,Owen N. Witte,Antoni Ribas	48
16	Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationbreakdown → 2010 ·Nature ·Ramin Nazarian,Hubing Shi,Qi Wang,Xiangju Kong,Richard C. Koya,Hane Lee,Zugen Chen,Mi‐Kyung Lee,Narsis Attar,Hooman Sazegar,Thinle Chodon,Stanley F. Nelson,Grant A. McArthur,Jeffrey A. Sosman,Antoni Ribas,Roger S. Lo	1614
17	CD4+CD25− T Cells Transduced to Express MHC Class I-Restricted Epitope-Specific TCR Synthesize Th1 Cytokines and Exhibit MHC Class I-Restricted Cytolytic Effector Function in a Human Melanoma Model 2008 ·The Journal of Immunology ·Arvind Chhabra,Lili Yang,Pin Wang,Begoña Comı́n-Anduix,Raja Das,Nitya G. Chakraborty,(unknown),Shikhar Mehrotra,Haiguang Yang,Cinnamon L Hardee,Roger P. Hollis,David I. Dorsky,Richard C. Koya,Donald B. Kohn,Antoni Ribas,James S. Economou,David Baltimore,Bijay Mukherji	36
18	The TLR-7 Agonist, Imiquimod, Enhances Dendritic Cell Survival and Promotes Tumor Antigen-Specific T Cell Priming: Relation to Central Nervous System Antitumor Immunity 2006 ·The Journal of Immunology ·Robert M. Prins,Noah Craft,Kevin W. Bruhn,Haumith Khan-Farooqi,Richard C. Koya,Renata Stripecke,Jeff F. Miller,Linda M. Liau	160
19	Frequent expression of new cancer/testis gene D40/AF15q14 in lung cancers of smokers 2002 ·British Journal of Cancer ·Masato Takimoto,Gang Wei,Hirotoshi Dosaka‐Akita,(unknown),Shunsuke Kondo,Noriaki Sakuragi,Itsuo Chiba,Toshiaki Miura,Naoki Itoh,(unknown),Richard C. Koya,Tadashi Tsukamoto,S Fujimoto,Hiroyuki Katoh,Noboru Kuzumaki	34
20	Analysis of the value of empiric vancomycin administration in febrile neutropenia occurring after autologous peripheral blood stem cell transplants 1998 ·Bone Marrow Transplantation ·Richard C. Koya,Janet Andersen,Hugo F. Fernández,Mark Goodman,Nelson Spector,Rebekah E. Smith,Joseph T. Hanlon,PA Cassileth	13

About Richard C. Koya

Richard C. Koya is a scholar working on Oncology, Immunology and Genetics, having authored 78 papers that have together received 7.5k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (28 papers), CAR-T cell therapy research (25 papers) and Melanoma and MAPK Pathways (16 papers). The work is most often cited by research in Oncology (4.2k citations), Immunology (2.2k citations) and Molecular Biology (4.6k citations). Richard C. Koya has collaborated with scholars based in United States, Brazil and Japan. Frequent co-authors include Antoni Ribas, Thinle Chodon, Roger S. Lo, Xiangju Kong, Hubing Shi, Jeffrey A. Sosman, Stephen Mok, Stanley F. Nelson, Hooman Sazegar and Narsis Attar. Their work appears in journals such as Nature, Proceedings of the National Academy of Sciences and Journal of the American Chemical Society.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact